Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
DORIBAX |
| Manufacturer |
|
Ortho-McNeil Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Carbapenem. |
| Generic Name |
|
Doripenem (as monohydrate) 500mg/vial; pwd; for IV infusion after constitution and dilution; preservative-free. |
| Indications |
|
Susceptible complicated intra-abdominal and complicated urinary tract infections (including pyelonephritis). |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Give by IV infusion over 1 hr; may switch to oral antibiotics after 3 days. ≥18yrs (CrCl >50mL/min): Intra-abdominal: 500mg every 8 hrs for 5–14 days. UTI, pyelonephritis: 500mg every 8 hrs for 10–14 days. CrCl 30–50mL/min: 250mg every 8 hrs; CrCl>10–<30mL/min: 250mg every 12 hrs. |
| Contraindications |
|
Beta-lactam allergy. |
| Precautions |
|
Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Antagonizes valproic acid (monitor valproate frequently). Potentiated by probenecid (not recommended). |
| Adverse Reactions |
|
Headache, nausea, diarrhea (may be serious; evaluate if occurs), rash, phlebitis, anemia, hypersensitivity reactions. |
| How Supplied |
|
Single-use vials—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
